NCT01528384View on ClinicalTrials.gov

Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Argininosuccinate Synthetase Deficient
Interventions
DRUG

ADI-PEG 20

4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Polaris Group
All Listed Sponsors
lead

Polaris Group

INDUSTRY